Physician
Nemkov, Melvin
Nemkov, Melvin was paid $582K by Medicaid between Jan 2018 and Jun 2023, across 7 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 39% of everything it billed.
33Billing provider infoNEMKOV, MELVIN
CHELMSFORD, MA 01824
CHELMSFORD, MA 01824
33aNPI1649325283assigned 01/24/2007
33bProvider typeInternal Medicine Physician
28Total paid$582K
24GClaims11,107
24DCodes billed7
24AFirst – last monthJan 2018 – Jun 2023
Compared with peers
Next to other Internal Medicine Physician providers in Massachusetts
Rank by total paid#68 of 1,270
Median peer was paid$8K
This provider vs. median70×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,457 | $110K | |
| 2019 | 2,230 | $99K | |
| 2020 | 2,465 | $131K | |
| 2021 | 2,138 | $127K | |
| 2022 | 1,266 | $81K | |
| 2023 | 551 | $34K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 39% | 4,750 | 1,910 | $225K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25% | 2,664 | 1,300 | $147K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 22% | 2,108 | 939 | $126K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13% | 777 | 406 | $74K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 363 | 248 | $6K |
| 81025 | <1% | 421 | 194 | $3K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 24 | 14 | $2K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.